The Misuse of Drugs (Amendment No.2) Regulations (Northern Ireland) 2012
S.R. 2012/213 · Made 22 May 2012
Dangerous Drugs
Made 22nd May 2012
Coming into operation 13th June 2012
In accordance with section 31(3) of that Act, it has consulted with the Advisory Council on the Misuse of Drugs.
Annotations to the whole text
Footnotes
- f1
-
1971 c.38 Section 22 of that Act was amended by section 177(1) of, and paragraph 12 of Schedule 4 to, the Customs and Excise Management Act 1979(c.2) and section 151 of, and paragraphs 1 and 14 of Schedule 18 to, the Police Reform and Social Responsibility Act 2011(c.13)
- f2
-
S.R &O.(N.I).1973 No.504, Article 5(a) and S.I. 1999 No.283(N.I.1) Article 3(6)
Contents
- 1Citation and commencement
- 2Interpretation
- 3Amendment of the Misuse of Drugs Regulations (Northern Ireland) 2002
- 4Amendment of the Misuse of Drugs Regulations (Northern Ireland) 2002
- 5Amendment of the Misuse of Drugs Regulations (Northern Ireland) 2002
- 6Amendment of the Misuse of Drugs Regulations (Northern Ireland) 2002
- Signature
- Explanatory note
1Citation and commencement
These Regulations may be cited as the Misuse of Drugs (Amendment No.2) Regulations (Northern Ireland) 2012 and shall come into operation on 13th June 2012.
2Interpretation
The Interpretation Act (Northern Ireland) 1954f1 shall apply to these Regulations as it applies to an Act of the Assembly
3Amendment of the Misuse of Drugs Regulations (Northern Ireland) 2002
The Misuse of Drugs Regulations (Northern Ireland) 2002f1 shall be amended as follows.
4Amendment of the Misuse of Drugs Regulations (Northern Ireland) 2002
In Schedule 1 (which specifies controlled drugs subject to the requirements of regulations 14, 15, 16, 18, 19, 20, 23, 26 and 27) after paragraph 1(n), insert—
“(o)Any compound (not being pipradrol) structurally derived from piperidine, pyrrolidine, azepane, morpholine or pyridine by substitution at a ring carbon atom with a diphenylmethyl group, whether or not the compound is further modified in any of the following ways, that is to say,
(i)by substitution in any of the phenyl rings to any extent with alkyl, alkoxy, haloalkyl or halide groups;
(ii)by substitution at the methyl carbon atom with an alkyl, hydroxyalkyl or hydroxy group;
(iii)by substitution at the ring nitrogen atom with an alkyl, alkenyl, haloalkyl or hydroxyalkyl group.”.
5Amendment of the Misuse of Drugs Regulations (Northern Ireland) 2002
In paragraph 1(a) of Schedule 3 (which specifies controlled drugs subject to the requirements of regulations 14, 15 (except Temazepam), 16, 18, 22, 23, 24, 26 and 27) after “Benzphetamine”, insert “7-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one”.
6Amendment of the Misuse of Drugs Regulations (Northern Ireland) 2002
In Schedule 3 for paragraphs 2, 3 and 4, substitute—
“2.Any stereoisomeric form of a substance specified in paragraph 1 or 3 not being phenylpropanolamine.
3.Any ester or ether of pipradrol.
4.Any salt of a substance specified in any of paragraphs 1 to 3.
5.Any preparation or other product containing a substance specified in any of paragraphs 1 to 4, not being a preparation specified in Schedule 5.”.
Signature
Sealed with the Official Seal of the Department of Health, Social Services and Public Safety on 22nd May 2012
(L.S.)
Norman Morrow
A senior officer of the Department of Health, Social Services and Public Safety
Explanatory note
(This note is not part of the Regulations)
These Regulations add, in regulation 3, desoxypipradrol and other pipradrol‑related compounds to Schedule 1 to the Misuse of Drugs Regulations (Northern Ireland) 2002 (the “2002 Regulations”).Regulation 4 adds 7‑bromo‑5‑(2‑chlorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one (commonly known as phenazepam), and regulation 5 adds any ester or ether of pipradrol, or any stereoisomeric form or salt or preparation or other product of such an ester or ether, to Schedule 3 to the 2002 Regulations. The schedule in which a controlled drug is placed primarily affects the extent to which the drug can be lawfully imported, exported, produced, supplied or possessed and dictates the record keeping, labelling and destruction requirements in relation to that drug.